<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         dtd-version="1.1"
         article-type="research-article"
         xml:lang="pt"
         specific-use="sps-1.8">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">psipesq</journal-id>
         <journal-title-group>
            <journal-title>Psicologia em Pesquisa</journal-title>
            <abbrev-journal-title abbrev-type="publisher">Psicol. pesq.</abbrev-journal-title>
         </journal-title-group>
         <issn pub-type="epub">1982-1247</issn>
         <publisher>
            <publisher-name>Programa de Pós-Graduação em Psicologia da UFJF</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.34019/1982-1247.2025.v20.43945</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Articles</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Características Sociodemográficas e Medidas de Saúde Mental em Usuários de Cogumelos Psicoativos</article-title>
            <trans-title-group xml:lang="en">
               <trans-title>Sociodemographic Characteristics and Measures of Mental Health in Users of Psychoactive Mushrooms.</trans-title>
            </trans-title-group>
            <trans-title-group xml:lang="es">
               <trans-title>Características Sociodemográficas y Medidas de Salud Mental en Usuarios de Hongos Psicoactivos</trans-title>
            </trans-title-group>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author">
               <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1819-6588</contrib-id>
               <name>
                  <surname>Bressiani</surname>
                  <given-names>Roger Andrade</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">
                  <sup>1</sup>
               </xref>
            </contrib>
            <contrib contrib-type="author">
               <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0336-3793</contrib-id>
               <name>
                  <surname>Morais</surname>
                  <given-names>Paulo Rogério</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">
                  <sup>2</sup>
               </xref>
            </contrib>
         </contrib-group>
         <aff id="aff1">
            <institution content-type="original">Universidade Federal de Rondônia. E-mail: roger.hab@gmail.com</institution>
            <institution content-type="normalized">Universidade Federal de Rondônia</institution>
            <institution content-type="orgname">Universidade Federal de Rondônia.</institution>
            <country country="BR">Brazil</country>
            <email>roger.hab@gmail.com</email>
         </aff>
         <aff id="aff2">
            <institution content-type="original">Universidade Federal de Rondônia. E-mail: paulo.morais@unir.br</institution>
            <institution content-type="normalized">Universidade Federal de Rondônia</institution>
            <institution content-type="orgname">Universidade Federal de Rondônia</institution>
            <country country="BR">Brazil</country>
            <email>paulo.morais@unir.br</email>
         </aff>
         <author-notes>
            <corresp id="c1">Informações do Artigo:
Roger Andrade Bressiani 
<email>roger.hab@gmail.com</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub">
            <year>2026</year>
         </pub-date>
         <volume>20</volume>
         <issue>1</issue>
         <fpage>1</fpage>
         <lpage>25</lpage>
         <history>
            <date date-type="received">
               <day>19</day>
               <month>03</month>
               <year>2024</year>
            </date>
            <date date-type="accepted">
               <day>01</day>
               <month>04</month>
               <year>2025</year>
            </date>
         </history>
         <permissions>
            <license xml:lang="pt" license-type="open-access"
                     xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
               <license-p>Este é um artigo publicado em acesso aberto sob uma licença Creative Commons</license-p>
            </license>
         </permissions>
         <abstract>
            <title>RESUMO</title>
            <bold> </bold>
            <p>Em um contexto de uso difundido de cogumelos psicoativos, o objetivo deste estudo foi descrever características sociodemográficas e medidas de saúde mental em uma amostra não-probabilística de usuários de cogumelos psicoativos no Brasil. A coleta on-line incluiu um questionário sociodemográfico e a Escala de Depressão, Ansiedade e Estresse (DASS-21). A amostra composta por 246 participantes, idade média de 29,5 anos (DP = 8,56), 54,1% homens, 83,7% com ensino superior ou mais e de todas as regiões do país apresentou maior prevalência de sintomatologia “Normal/Leve” para as três condições avaliadas, com uma parcela reduzida apresentando sintomas mais graves.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>ABSTRACT	</title>
            <bold> </bold>
            <p>In a context of widespread use of psychoactive mushrooms, the objective of this study was to describe the sociodemographic characteristics and mental health measures in a non-probabilistic sample of psychoactive mushroom users in Brazil. The online data collection included a sociodemographic questionnaire and the Depression, Anxiety, and Stress Scale (DASS-21). The sample, consisting of 246 participants with an mean age of 29.5 years (SD = 8.56), 54.1% male, 83.7% with higher education or more, and from all regions of the country, showed a higher prevalence of 'Normal/Mild' symptomatology for the three conditions evaluated, with a small proportion presenting more severe symptoms.</p>
         </trans-abstract>
         <trans-abstract xml:lang="es">
            <title>RESUMEN</title>
            <bold> </bold>
            <p>En un contexto de uso difundido de hongos psicoactivos, el objetivo de este estudio fue describir las características sociodemográficas y medidas de salud mental en una muestra no probabilística de usuarios de hongos psicoactivos en Brasil. La recogida de datos en línea incluyó un cuestionario sociodemográfico y la Escala de Depresión, Ansiedad y Estrés (DASS-21). La muestra, compuesta por 246 participantes con una edad media de 29,5 años (DE = 8,56), 54,1% hombres, y 83,7% con educación superior o más, provenientes de todas las regiones del país, mostró una mayor prevalencia de sintomatología "Normal/Leve" para las tres condiciones evaluadas, con una pequeña proporción que presentó síntomas más graves.</p>
         </trans-abstract>
         <kwd-group xml:lang="pt">
            <title>PALAVRAS-CHAVE:</title>
            <kwd>Psilocybe cubensis</kwd>
            <kwd>Demografia</kwd>
            <kwd>Depressão</kwd>
            <kwd>Ansiedade</kwd>
            <kwd>Estresse</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <title>KEYWORDS:</title>
            <kwd>Psilocybe cubensis</kwd>
            <kwd>Demographics</kwd>
            <kwd>Depression</kwd>
            <kwd>Anxiety</kwd>
            <kwd>Stress.</kwd>
         </kwd-group>
         <kwd-group xml:lang="es">
            <title>PALABRAS CLAVE:</title>
            <kwd>Psilocybe cubensis</kwd>
            <kwd>Demografía</kwd>
            <kwd>Depresión</kwd>
            <kwd>Ansiedad</kwd>
            <kwd>Estrés</kwd>
         </kwd-group>
         <counts>
            <fig-count count="0"/>
            <table-count count="4"/>
            <equation-count count="0"/>
            <ref-count count="59"/>
            <page-count count="25"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>Cogumelos psicoativos têm sido utilizados ao longo de milênios em diferentes culturas com objetivos religiosos e terapêuticos. No Império Asteca, os cogumelos eram incorporados em cerimônias de oferendas divinas e estudos etnobotânicos elucidaram o uso moderno de pelo menos 20 espécies de cogumelos em tribos no sul do México (<xref ref-type="bibr" rid="B15">Edmundo, 2020</xref>; <xref ref-type="bibr" rid="B18">Fanhofmann, 2019</xref>; <xref ref-type="bibr" rid="B24">Griffiths et al., 2006)</xref>. Muitos desses cogumelos contêm psilocibina, um triptamina extraordinariamente biodinâmica com uma cadeia lateral fosforilada, e um derivado instável, a psilocina <xref ref-type="bibr" rid="B53">(Schultes, 1969)</xref>.</p>
      <p>A psilocibina é naturalmente presente em cogumelos do gênero <italic>Psilocybe</italic> e no organismo é metabolizada em psilocina (4-hidroxi-N,N-dimetiltriptamina), que apresenta estrutura química semelhante à serotonina e pode atravessar a barreira hematoencefálica e atua como agonista nos receptores da serotonina 5-HT2A, sendo responsável pelos efeitos psicodélicos <xref ref-type="bibr" rid="B42">(Passie et al., 2002)</xref>. Os efeitos psicológicos da psilocibina, semelhantes a outros psicodélicos, incluem alterações significativas na percepção, cognição, afetividade, volição e funções somestésicas. Estes podem envolver mudanças sensoriais, flutuações de humor e fenômenos dissociativos <xref ref-type="bibr" rid="B24">(Griffiths et al., 2006)</xref>. Além disso, demonstra potencial para aumentar o bem-estar e reduzir o sofrimento psicológico, o que tem suscitado interesse em seu uso para o estudo do cérebro e doenças mentais <xref ref-type="bibr" rid="B15">(Edmundo, 2020)</xref>.</p>
      <p>A psilocibina tem sido extensivamente estudada, incluindo ensaios clínicos para depressão maior unipolar resistente ao tratamento e depressão e ansiedade em pacientes com câncer e risco de vida <xref ref-type="bibr" rid="B58">
            <xref ref-type="bibr" rid="B8">(Carhart-Harris et al., 2016</xref>, <xref ref-type="bibr" rid="B9">2017</xref>, <xref ref-type="bibr" rid="B10">2018</xref>; <xref ref-type="bibr" rid="B23">Griffiths et al., 2016</xref>; <xref ref-type="bibr" rid="B25">Grob et al., 2011</xref>; <xref ref-type="bibr" rid="B48">Roseman et al., 2018</xref>; <xref ref-type="bibr" rid="B50">Ross et al., 2016</xref>; <xref ref-type="bibr" rid="B58">Watts et al., 2017</xref>)</xref>. A FDA (<italic>Food and Drug Administration</italic>) concedeu permissões para estudos de fase 3 com psilocibina no tratamento de sofrimento relacionado ao fim de vida e depressão persistente (<xref ref-type="bibr" rid="B14">Doblin, 2015</xref>; <xref ref-type="bibr" rid="B38">Nichols, 2014</xref>; <xref ref-type="bibr" rid="B44">Phelps, 2017)</xref>.</p>
      <p>Apesar das predominantes políticas proibicionistas das substâncias psicodélicas, elas são amplamente empregadas em contextos não clínicos ou científicos, abrangendo várias partes do globo. Tal uso ocorre por motivos de curiosidade, experiências místicas e introspecção <xref ref-type="bibr" rid="B31">(Krebs &amp; Johansen, 2013)</xref>. Legalmente, tanto a psilocibina quanto a psilocina em suas formas extraídas figuram na Lista de Substâncias Psicotrópicas proibidas no Brasil <xref ref-type="bibr" rid="B36">(Ministério da Saúde, 1998</xref>). No entanto, os cogumelos contendo psilocibina não estão abrangidos por essa regulamentação. No Brasil, esses cogumelos são utilizados recreativamente <italic>in natura</italic>, de maneira recreacional e hedonista, em parte devido à facilidade de aquisição on-line, à sua abundância devido à pecuária, assim como à ausência de regulamentação <xref ref-type="bibr" rid="B17">(Diniz, 1999; Escobar &amp; Roazzi, 2010)</xref>.</p>
      <p>Uma pesquisa nos EUA baseada em dados de 2010 estimou que mais de 32 milhões de pessoas utilizaram psicodélicos, incluindo psilocibina, LSD e mescalina <xref ref-type="bibr" rid="B31">(Krebs &amp; Johansen, 2013)</xref>. O uso de psilocibina é particularmente comum entre jovens adultos, uma tendência impulsionada pelo acesso facilitado às informações sobre instruções acerca de como encontrar cogumelos selvagens, cultivo doméstico, bem como sobre seus efeitos e formas de utilização <xref ref-type="bibr" rid="B13">(Diniz, 1999; Krebs &amp; Johansen, 2013)</xref>.</p>
      <p>Um estudo etnográfico visou identificar características de indivíduos em comunidades on-line sobre drogas psicoativas (e-psiconautas) e descobriu-se que 21% teve sua primeira experiência psicodélica com cogumelos psicoativos, dos quais cerca de 13% reportaram uso regular e os fungos com psilocibina (<italic>Psilocybe cubensis</italic>/<italic>cyanescens</italic>/<italic>semilanceata</italic> /<italic>azurescens</italic>) foram os mais populares (85%) <xref ref-type="bibr" rid="B40">(Orsolini et al., 2015)</xref>.</p>
      <p>O III Levantamento Nacional sobre o Uso de Drogas pela População Brasileira apontou que 1,1% e 0,71% dos brasileiros entre 12 e 65 anos já consumiram alucinógenos (LSD, Ayahuasca e cogumelos) e MDMA/Ecstasy, respectivamente <xref ref-type="bibr" rid="B2">(Bastos et al., 2017)</xref>, pelo menos uma vez na vida. Este mesmo levantamento destacou o predomínio do uso de álcool (66,4%) e tabaco (33,5%), evidenciando o elevado índice de dependência com essas substâncias (Bastos et al., 2017). O <italic>Global Drug Survey</italic> (GDS) de 2020, que abrangeu mais de 900.000 participantes em 25 países, revelaram que 16,1% dos respondentes relataram o uso de cogumelos psicoativos no último ano <xref ref-type="bibr" rid="B59">(Winstock et al., 2021)</xref>. Uma seção específica sobre cogumelos mágicos, respondida por 11.000 participantes, evidenciou diversas motivações para o uso, incluindo tratamento psiquiátrico (13,2%), busca por bem-estar (55%) e enfrentamento de preocupações emocionais (31,7%). O Brasil foi o sexto país com o maior número de respondentes (4,7%) nessa seção. Os padrões predominantes de uso foi de 1 a 10 vezes no último ano (55,5%), seguido pelo uso em uma única ocasião (34,1%) <xref ref-type="bibr" rid="B59">(Winstock et al., 2021</xref>).</p>
      <p>Efeitos adversos decorrentes do uso de cogumelos psicoativos envolvem a necessidade de gerenciar a ansiedade durante a experiência, especialmente relacionada a distorções de pensamentos. Altas doses, uso simultâneo com outras substâncias e múltiplas doses estão associados a emergências <xref ref-type="bibr" rid="B3">(Bienemann et al., 2020)</xref>. Embora possa elevar moderadamente a pressão arterial e causar dores de cabeça temporárias, a psilocibina tem perfil de risco baixo e alta segurança, mesmo em ambientes não supervisionados. Ainda que haja desenvolvimento de tolerância, não tem potencial de causar dependência. Diferentemente de outras substâncias, os agonistas dos receptores 5-HT2A, como a psilocibina, não apresentam efeitos que levam ao vício, pois não afetam diretamente os sistemas dopaminérgicos do cérebro (<xref ref-type="bibr" rid="B39">Nichols, 2016</xref>; <xref ref-type="bibr" rid="B42">Passie et al., 2002</xref>; <xref ref-type="bibr" rid="B52">Schenberg, 2018)</xref>.</p>
      <p>Durante o período pandêmico, estudos revelaram 60% dos participantes relatando estresse elevado, 57,5% ansiedade e 26% depressão, além de associações significativas entre essas condições <xref ref-type="bibr" rid="B32">(Lipp &amp; Lipp, 2020, 2022)</xref>. Em 2022, após o período mais crítico da pandemia, <xref ref-type="bibr" rid="B33">Lipp et al. (2023)</xref> identificaram uma redução nesses índices, com 24% de prevalência de estresse, 36,6% de ansiedade e 26% de depressão.</p>
      <p>Diante do cenário de desafios crescentes à saúde mental e do uso difundido de cogumelos psicoativos, o presente estudo teve o objetivo de descrever as características sociodemográficas e medidas de saúde mental em uma amostra não-probabilística de usuários de cogumelos psicoativos do gênero <italic>Psilocybe cubensis</italic> no Brasil.</p>
      <sec sec-type="materials|methods">
         <title>Método</title>
         <bold> </bold>
         <p>Trata-se de um estudo descritivo, com delineamento transversal e abrangência nacional. O recrutamento de participantes se deu por meio da veiculação de postagens nas redes sociais Instagram, Facebook, WhatsApp e Telegram, seguindo o método bola de neve <xref ref-type="bibr" rid="B4">(Biernacki &amp; Waldorf, 1981</xref>; <xref ref-type="bibr" rid="B10">Daldegan-Bueno et al., 2022</xref>; <xref ref-type="bibr" rid="B37">Morais et al., 2022)</xref>. Os instrumentos usados para a coleta de dados foram dispostos em um formulário on-line para autopreenchimento. O questionário ficou disponível nessas redes sociais para preenchimento entre os meses de fevereiro e setembro de 2022.</p>
         <p>Os critérios para inclusão na amostra foram: idade igual ou superior a 18 anos, autorrelato do uso de cogumelos psicoativos em pelo menos uma vez na vida em que os efeitos tenham sido percebidos.</p>
         <p>Para a coleta dos dados foram empregados os seguintes instrumentos e escalas: </p>
         <p>Questionário Sociodemográfico, Socioeconômico e Histórico Clínico: composto por questões necessárias para a caracterização da amostra, incluindo informações sobre gênero (masculino, feminino e outros que não se identificam com a classificação binária), idade, estado civil, número de filhos, condições de habitação, renda, religião, escolaridade, ocupação (estudantes, trabalhadores e aqueles que não se identificam com as demais classificações), local de residência, e histórico de uso de substâncias psicoativas.</p>
         <p>Escala de Depressão, Ansiedade e Estresse, versão reduzida (DASS-21): composta por 21 itens, respondidos em escala Likert de quatro pontos, e sub agrupados em subescalas específicas para avaliar sintomas de depressão, ansiedade e estresse <xref ref-type="bibr" rid="B35">(Lovibond &amp; Lovibond, 2004)</xref>. Este instrumento foi adaptado e validado para o português do Brasil e apresentaram bons indicadores psicométricos <xref ref-type="bibr" rid="B56">(Vignola, 2013</xref>; <xref ref-type="bibr" rid="B57">Vignola &amp; Tucci, 2014</xref>). Para depressão, os pontos de corte são: Normal/Leve: 0-9; Mínimo: 10-13; Moderado: 14-20; Grave: 21-27; Muito Grave: 28+. Para ansiedade: Normal/Leve: 0-7; Mínimo: 8-9; Moderado: 10-14; Grave: 15-19; Muito Grave: 20+. E para estresse: Normal/Leve: 0-14; Mínimo: 15-18; Moderado: 19-25; Grave: 26-33; Muito Grave: 34+ (Lovibond &amp; Lovibond, 2004).</p>
         <p>Os instrumentos foram formatados e organizados no Google Forms (https://www.google.com/forms/about/) em seções sequenciais. Os participantes que acessaram o <italic>link</italic> divulgado foram direcionados para uma página com informações sobre a pesquisa e o termo de consentimento. Aqueles que concordaram em participar foram direcionados aos formulários referentes aos instrumentos. Ao final da coleta, os dados foram salvos em uma planilha na plataforma do Google e exportados para uma planilha compatível com os programas IBM SPSS Statistics (versão 24.0). Antes das análises, os dados foram submetidos à avaliação crítica para identificação e tratamento das inconsistências no preenchimento (por exemplo: diferentes entradas de idade, como anos totais vividos; detecção e exclusão de respostas duplicadas etc.). Nesta etapa também foram criados códigos numéricos para as respostas das variáveis categóricas.</p>
         <p>A análise das variáveis categóricas foi conduzida com base nas frequências absolutas de cada categoria, empregado o teste qui-quadrado. Em todas as análises foi adotado o nível de significância de 5%.</p>
         <p>Este protocolo de pesquisa foi aprovado pelo Comitê de Ética em Pesquisa da Universidade Federal de Rondônia sob o número CAAE 54105821.7.0000.5300.</p>
      </sec>
      <sec sec-type="results">
         <title>Resultados</title>
         <bold> </bold>
         <p>Um total de 264 indivíduos responderam ao formulário eletrônico. Após o processamento inicial dos dados, alguns destes não foram incluídos na amostra devido a critérios como idade inferior a 18 anos (dois), respostas incompletas (um) e inconsistências nos formulários, como ter informado que nunca utilizou cogumelos ou psicodélicos (15), totalizando 18 respondentes excluídos. A amostra final foi composta por 246 indivíduos. As características sociodemográficas e socioeconômicas estão apresentadas na <xref ref-type="table" rid="t1">Tabela 1</xref>.</p>
         <p>Observou-se uma maioria de homens (54,1%) na amostra, com idade média de 29,5 anos. A maioria dos participantes era solteira ou em relacionamentos casuais (64,4%), não tinha filhos (79,7%), possuía educação avançada (83,7%). A ocupação principal era de trabalhadores (70,7%) e a maioria (55,7%) ganhava até 4 salários-mínimos.</p>
         <p>
            <table-wrap id="t1">
               <label>Tabela 1</label>
               <caption>
                  <title>Características Sociodemográficas e Socioeconômicas de Usuários de Cogumelos Psicoativos (N = 246).</title>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th align="center">Variável</th>
                        <th align="center"> </th>
                        <th align="center">N (%)</th>
                        <th align="center">χ² (df); p</th>
                     </tr>
 
                  </thead>
                  <tbody>
                     <tr>
                        <td align="center">Sexo/Gênero</td>
                        <td align="center">Masculino<sub>a</sub>
Feminino<sub>a</sub>
Outros/Não-binário<sub>b</sub>
                        </td>
                        <td align="center">133 (54,1)
105 (42,7)
8 (3,3)</td>
                        <td align="center">105 (2); &lt;0,001</td>
                     </tr>
 
                     <tr>
                        <td align="center">Idade em anos [média (DP)]</td>
                        <td align="center"> </td>
                        <td align="center">29,5 (8,56)</td>
                        <td align="center"> </td>
                     </tr>
 
                     <tr>
                        <td align="center">Situação conjugal</td>
                        <td align="center">Solteiro (a)/Relacionamento casual<sub>a</sub>
Casado(a)/mora com parceiro(a)<sub>a</sub>
Divorciada(o)/Separada(o)/Viúva(o)<sub>b</sub>
                        </td>
                        <td align="center">159 (64,4)
74 (30,1)
13 (5,3)</td>
                        <td align="center">131 (2); p &lt;0,001</td>
                     </tr>
 
                     <tr>
                        <td align="center">Possui filhos</td>
                        <td align="center">Sim<sub>a</sub>
Não<sub>b</sub>
                        </td>
                        <td align="center">50 (20,3)
196 (79,7)</td>
                        <td align="center">87 (1); p &lt;0,001</td>
                     </tr>
 
                     <tr>
                        <td align="center">Com quantas pessoas moram [média (DP)]</td>
                        <td align="center"> </td>
                        <td align="center">1,91
(1,49)</td>
                        <td align="center"> </td>
                     </tr>
 
                     <tr>
                        <td align="center">Nível de escolaridade</td>
                        <td align="center">Educação Avançada (Graduação/Pós-graduação)<sub>a</sub>
Educação básica (igual ou inferior ao ensino médio)<sub>b</sub>
                        </td>
                        <td align="center">206 (83,7)

40 (16,3)</td>

                        <td align="center">112 (1); p &lt;0,001</td>
                     </tr>
 
                     <tr>
                        <td align="center">Ocupação</td>
                        <td align="center">Estudantes<sub>a</sub>
Trabalhadores<sub>b</sub>
Não estuda/trabalha<sub>c</sub>
                        </td>
                        <td align="center">60 (24,4)
174 (70,7)
12 (4,9)</td>
                        <td align="center">169 (2); p &lt;0,001</td>
                     </tr>
 
                     <tr>
                        <td align="center">Renda Familiar</td>
                        <td align="center">Até 4 salários mínimos<sub>a</sub>
Acima de 4 salários mínimos<sub>a</sub>
                        </td>
                        <td align="center">137 (55,7)
109 (44,3)</td>
                        <td align="center">3 (1); p 0,074</td>
                     </tr>
 
                     <tr>
                        <td align="center">Religião</td>
                        <td align="center">Sem religião / Ateu<sub>a</sub>
Com religião<sub>a</sub>
                        </td>
                        <td align="center">143 (58,1)
103 (41,9)</td>
                        <td align="center">7 (1); p 0,011</td>
                     </tr>
 
                     <tr>
                        <td align="center">Prática religiosa</td>
                        <td align="center">Praticantes (com religião)<sub>a</sub>
Não Praticantes (com religião)<sub>a</sub>
                        </td>
                        <td align="center">60 (59,4)
41 (40,6)</td>
                        <td align="center">4 (1) p 0,59</td>
                     </tr>
 
                     <tr>
                        <td align="center">Região (residência)</td>
                        <td align="center">Norte<sub>a</sub>
Nordeste<sub>b</sub>
Centro-Oeste<sub>b</sub>
Sudeste<sub>c</sub>
Sul<sub>b</sub>
                        </td>
                        <td align="center">61 (24,8)
28 (11,4)
18 (7,3)
118 (48,0)
21 (8,5)</td>
                        <td align="center">144 (4); p &lt;0,001</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="TFN1">
                     <p>
                        <italic>Nota. </italic>Cada letra de subscrito denota um subconjunto de categorias de frequências com proporções de coluna que não diferem significativamente entre si no nível de 0,05.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </p>
         <p>No que diz respeito à religião, a maioria se identificou como sem religião ou ateus (58,1%). Em termos de região de residência, a maioria dos participantes morava no Sudeste (48%), seguido pelo Norte (24,8%), Nordeste (11,4%), Sul (8,5%) e Centro-Oeste (7,3%).</p>
         <p>
            <table-wrap id="t2">
               <label>Tabela 2</label>
               <caption>
                  <title>Conhecimento Prévio dos Indivíduos sobre Cogumelos Psicoativos (N = 264).</title>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th align="center">Variável</th>
                        <th align="center">N (%)</th>
                        <th align="center">χ² (df); p</th>
                     </tr>
 
                  </thead>
                  <tbody>
                     <tr>
                        <td align="left">Conhecimento sobre os cogumelos psicoativos.
Sim<sub>a</sub>
Não<sub>b</sub>
                        </td>
                        <td align="left">
238 (96,7)
8 (3,3)</td>
                        <td align="center">
215 (1); p &lt; 0,001</td>
                     </tr>
 
                     <tr>
                        <td align="left">Conhecimento sobre os efeitos esperados.
Sim<sub>a</sub>
Não / Não tinha certeza<sub>b</sub>
                        </td>
                        <td align="left">
174 (70,7)
72 (29,3)</td>
                        <td align="center">
144 (4); p &lt; 0,001</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="TFN2">
                     <p>
                        <italic>Nota. </italic>Cada letra de subscrito denota um subconjunto de categorias de frequências com proporções de coluna que não diferem significativamente entre si no nível de 0,05.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </p>
         <p>Quase a totalidade da amostra (96,7%) afirmou ter algum conhecimento sobre os cogumelos psicoativos e 70,7% dos participantes afirmaram ter conhecimento sobre os efeitos esperados conforme mostrado na <xref ref-type="table" rid="t2">Tabela 2</xref>.</p>
         <bold> </bold>
         <p>A respeito da prevalência de sintomas de depressão, ansiedade e estresse (<xref ref-type="table" rid="t3">Tabela 3</xref>), a maioria dos participantes apresentou sintomas na faixa "Normal/Leve" (58,1% para Depressão; 57,3% para Ansiedade; e 64,6% para Estresse) conforme medido pelo instrumento DASS-21. </p>
         <p>
            <table-wrap id="t3">
               <label>Tabela 3</label>
               <caption>
                  <title>Sintomas de Depressão, Ansiedade e Estresse (Dass-21) em Usuários de Cogumelos Psicoativos (N = 246).</title>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th align="center"> 
DASS-21</th>
                        <th align="center">Depressão
N (%)</th>
                        <th align="center">χ² (df);
p</th>
                        <th align="center">Ansiedade
N (%)</th>
                        <th align="center">χ² (df);
p</th>
                        <th align="center">Estresse
N (%)</th>
                        <th align="center">χ² (df);
p</th>
                     </tr>
 
                  </thead>
                  <tbody>
                     <tr>
                        <td align="left">Normal/Leve
Mínimo
Moderado
Grave
Muito Grave</td>
                        <td align="center">143 (58,1)<sub>a</sub>
28 (11,4)<sub>b</sub>
30 (12,2)<sub>b</sub>
19 (7,7)<sub>b</sub>
26 (10,6)<sub>b</sub>
                        </td>
                        <td align="center">
224 (4);
p &lt;0,001</td>
                        <td align="center">141 (57,3)<sub>a</sub>
15 (6,1)<sub>b</sub>
37 (15)<sub>c</sub>
23 (9,3)<sub>b,c</sub>
30 (12,2)<sub>b,c</sub>
                        </td>
                        <td align="center">
219 (4);
p &lt;0,001</td>
                        <td align="center">159 (64,6)<sub>a</sub>
24 (9,8)<sub>b</sub>
33 (13,4)<sub>b,c</sub>
19 (7,7)<sub>b,c</sub>
11 (4,5)<sub>b</sub>
                        </td>
                        <td align="center">
311 (4);
p &lt;0,001</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="TFN3">
                     <p>
                        <italic>Nota.</italic> Cada letra de subscrito denota um subconjunto de categorias de frequências com proporções de coluna que não diferem significativamente entre si no nível de 0,05.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </p>
         <p>Cerca de 18% dos participantes foram identificados como tendo sintomas de depressão classificados como “Graves” ou “Muito Graves”, e 21,5% alcançaram pontuações indicativas de sintomas “Graves” ou “Muito Graves” de ansiedade, enquanto 12,2% apresentaram sintomas de estresse nessas categorias.</p>
         <p>
            <table-wrap id="t4">
               <label>Tabela 4</label>
               <caption>
                  <title>Indicadores do Uso de Substâncias Psicoativas (N = 246).</title>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th align="center">Substâncias / N (%)</th>
                        <th align="center">Nunca</th>
                        <th align="center">Uso na vida</th>
                        <th align="center">Uso no último ano</th>
                        <th align="center">Uso no último mês</th>
                        <th align="center">χ² (df); p</th>
                     </tr>
 
                  </thead>
                  <tbody>
                     <tr>
                        <td align="left">Álcool
Tabaco
Maconha
Cocaína
Crack/Merla/Oxi
Anfetaminas
Psicodélicos
Opioides
Sedativos</td>
                        <td align="left">1 (0,4)<sub>a</sub>
18 (7,3)<sub>a</sub>
12 (4,9)<sub>a</sub>
138 (56,1)<sub>a</sub>
227 (92,3)<sub>a</sub>
162 (65,9)<sub>a</sub>
0 (0,0)<sub>a</sub>
207 (84,1)<sub>a</sub>
141 (57,3)<sub>a</sub>
                        </td>
                        <td align="left">109 (44,3)<sub>b</sub>
121 (49,2)<sub>b</sub>
99 (40,2)<sub>b</sub>
79 (32,1)<sub>b</sub>
17 (6,9)<sub>b</sub>
58 (23,6)<sub>b</sub>
97 (39,4)<sub>b</sub>
29 (11,8)<sub>b</sub>
67 (27,2)<sub>b</sub>
                        </td>
                        <td align="left">37 (15,0)<sub>c</sub>
35 (14,2)<sub>c</sub>
25 (10,2)<sub>c</sub>
21 (8,5)<sub>c</sub>
2 (0,8)<sub>c</sub>
14 (5,7)<sub>c</sub>
54 (22,0)<sub>c</sub>
4 (1,6)<sub>c</sub>
22 (8,9)<sub>c</sub>
                        </td>
                        <td align="left">99 (40,2)<sub>b</sub>
72 (29,3)<sub>d</sub>
110 (44,7)<sub>b</sub>
8 (3,3)<sub>d</sub>
0 (0,0)<sub>c</sub>
12 (4,9)<sub>c</sub>
95 (38,6)<sub>b</sub>
6 (2,4)<sub>c</sub>
16 (6,5)<sub>c</sub>
                        </td>
                        <td align="center">129 (3); p &lt;0,001
102 (3); p &lt;0,001
123 (3); p &lt;0,001
173 (3); p &lt;0,001
587 (3); p &lt;0,001
241 (3); p &lt;0,001
99 (3); p &lt;0,001
465 (3); p &lt;0,001
162 (3); p &lt;0,001</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="TFN4">
                     <p>
                        <italic>Nota.</italic> Cada letra de subscrito denota um subconjunto de categorias de frequências com proporções de coluna que não diferem significativamente entre si no nível de 0,05. Adotou-se o termo “psicodélicos” visando identificar o uso pregresso de substâncias com propriedades psicodélicas sem especificar as substâncias.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </p>
         <p>Com relação ao uso de outras substâncias psicoativas entre os participantes (<xref ref-type="table" rid="t4">Tabela 4</xref>), foi observado uso recente (no mês) de maconha (44,7%), álcool (40,2%) e psicodélicos (38,6%). O uso recente de opioides, cocaína, anfetaminas e sedativos foi reportado por menos de 10% dos participantes. Nenhum participante relatou uso de crack, merla ou oxi no último mês.</p>
      </sec>
      <sec sec-type="discussion">
         <title>Discussão</title>
         <bold> </bold>
         <p>Este estudo revela um perfil sociodemográfico de usuários de cogumelos psicoativos no Brasil caracterizado predominantemente por jovens adultos do sexo masculino, solteiros ou em relacionamentos casuais, sem filhos e com educação formal avançada (ensino superior ou pós-graduação), com algum trabalho formal e que não seguem alguma religião. Este perfil alinha-se com amostras de pesquisas internacionais sobre usuários de psicodélicos em diversos países, como Estados Unidos, Reino Unido, Austrália/Nova Zelândia, Canadá, Noruega e países da União Europeia (<xref ref-type="bibr" rid="B40">Orsolini et al., 2015</xref>; <xref ref-type="bibr" rid="B46">Roberts et al., 2020</xref>; <xref ref-type="bibr" rid="B47">Rootman et al., 2021</xref>; <xref ref-type="bibr" rid="B49">Rosenbaum et al., 2020)</xref>.</p>
         <p>O consumo de outras substâncias psicoativas entre usuários de cogumelos psicoativos apresenta padrões distintos comparado à população brasileira em geral. Dados do III Levantamento Nacional sobre o Uso de Drogas pela População Brasileira <xref ref-type="bibr" rid="B2">(Bastos et al., 2017)</xref> indicam que a população brasileira, em geral, relatou maior uso de álcool em algum momento da vida (66,4%), comparado à amostra (44,3%). Contudo, a prevalência do uso recente (últimos 30 dias) de álcool, tabaco, cocaína/crack e maconha foi maior entre os usuários de cogumelos do que na população geral. Esses resultados sugerem que usuários de cogumelos psicoativos, em comparação a população brasileira, em geral, apresentam um consumo mais elevado de substâncias lícitas e ilícitas. Essa maior exposição a outras substâncias psicoativas entre os usuários de cogumelos sugere a necessidade de investigar fatores de risco e proteção associados a esse comportamento. Convém observar que estudos associam o uso de substâncias psicodélicas em ambientes naturalistas, incluindo os cogumelos, à redução no consumo de substâncias como álcool e tabaco, entre outras drogas (<xref ref-type="bibr" rid="B20">Garcia-Romeu et al., 2019</xref>, <xref ref-type="bibr" rid="B19">2020</xref>; <xref ref-type="bibr" rid="B28">Johnson et al., 2017b)</xref>. Além disso, ensaios clínicos com o princípio ativo dos cogumelos, a psilocibina, sustentam seu potencial terapêutico para o tratamento de dependência <xref ref-type="bibr" rid="B5">(Bogenschutz et al., 2022</xref>; <xref ref-type="bibr" rid="B26">Johnson et al., 2014</xref>; <xref ref-type="bibr" rid="B55">Meer et al., 2023)</xref>.</p>
         <p> É importante mencionar que a coleta de dados ocorreu no período pós-pandêmico da COVID-19, fase marcada por adversidades significativas para a saúde mental. A instabilidade política e financeira do período pode ter exercido influência na saúde mental dos participantes deste estudo, assim como os padrões de consumo de substâncias psicoativas, considerando o aumento no consumo de álcool e outras drogas na população em decorrência do contexto vivenciado durante a pandemia de COVID-19 (<xref ref-type="bibr" rid="B1">Amorim &amp; Santos, 2022</xref>; <xref ref-type="bibr" rid="B45">Ramos et al., 2024)</xref>.</p>
         <p>Com relação aos sintomas de depressão, ansiedade e estresse, um estudo brasileiro apontou que, embora atenuadas em comparação ao período mais crítico da pandemia, as prevalências destas condições clínicas ainda se mantiveram superiores aos níveis de anos anteriores à pandemia <xref ref-type="bibr" rid="B34">(Lipp et al., 2023)</xref>. No presente estudo, em mais da metade da amostra foi observada ausência de sintomas clinicamente relevantes de depressão, ansiedade e estresse. A proporção de participantes que apresentaram sintomas classificados como “Graves” ou “Muito Graves” foi estatisticamente menor do que aqueles com escores indicativos de ausência ou baixa sintomatologia para as três condições avaliadas. Embora o delineamento empregado não permita estabelecer relação causal entre o uso de cogumelos e a baixa prevalência de sintomatologias severas das condições avaliadas, nossos achados são coerentes com os resultados de ensaios clínicos demonstrando que a psilocibina, utilizada sob condições de apoio psicológico, pode reduzir os sintomas de depressão e ansiedade e melhorar a qualidade de vida de pacientes com doenças graves, especialmente em casos de sofrimento psicológico e existencial <xref ref-type="bibr" rid="B23">(Griffiths et al., 2016</xref>; <xref ref-type="bibr" rid="B50">Ross et al., 2016)</xref>. Outros estudos corroboram esses achados, mostrando que a psilocibina, quando administrada com suporte psicológico, promove melhorias nos sintomas de depressão e ansiedade, mudanças positivas na personalidade e bem-estar, apontando que a qualidade da experiência psicodélica aguda é um mediador dessas mudanças <xref ref-type="bibr" rid="B7">(Carhart-Harris et al., 2018</xref>; <xref ref-type="bibr" rid="B11">Davis et al., 2021</xref>; <xref ref-type="bibr" rid="B16">Erritzoe et al., 2018</xref>; <xref ref-type="bibr" rid="B47">Rootman et al., 2021</xref>; <xref ref-type="bibr" rid="B48">Roseman et al., 2018)</xref>.</p>
         <p>No estudo de <xref ref-type="bibr" rid="B12">Davis et al. (2019)</xref>, são relatadas melhorias em quadros de depressão e ansiedade após o uso de 5-MeO-DMT em grupos naturalistas, com a intensidade das experiências místicas e o significado atribuído a elas associados a essas melhorias. Resultados semelhantes foram observados com outros psicodélicos, como a psilocibina e o LSD, que demonstraram eficácia na redução do consumo problemático de álcool <xref ref-type="bibr" rid="B20">(Garcia-Romeu et al., 2019)</xref> e na cessação do tabagismo (<xref ref-type="bibr" rid="B27">Johnson et al., 2017a</xref>, <xref ref-type="bibr" rid="B28">2017b)</xref> em contextos naturalistas. Em consonância com estes achados, os resultados do presente estudo sugerem que a utilização de cogumelos psicoativos em contextos naturalísticos, fora de ambientes clínicos ou de pesquisa, também pode ter potencial terapêutico. <xref ref-type="bibr" rid="B40">Orsolini et al. (2015</xref>, <xref ref-type="bibr" rid="B41">2017</xref>) observaram que indivíduos que consomem regularmente substâncias psicoativas em contextos naturalísticos e adotam práticas responsáveis durante as experiências (os psiconautas), apresentam um padrão de consumo que remete às práticas rituais xamânicas, com preferência por substâncias enteógenas/psicodélicas, visando alguns benefícios evolutivos e terapêuticos.</p>
         <p>Embora os achados desse estudo não permitam estabelecer relações causais entre o uso de cogumelos e a saúde mental, eles dialogam com a literatura que sugere o potencial dos psicodélicos na promoção da saúde mental tanto em contextos clínicos controlados, quanto em ambientes naturalísticos. Esses potenciais benefícios terapêuticos oferecem perspectivas alternativas para o uso não médico de substâncias psicodélicas, por exemplo, o uso psiconáutico. Contudo, a complexidade dessas experiências vai além da simples ingestão da substância, pois fatores contextuais, como o ambiente, o suporte disponível, e a qualidade da experiência, desempenham um papel fundamental na modulação dos efeitos imediatos e de longo prazo dos psicodélicos (<xref ref-type="bibr" rid="B16">Erritzoe et al., 2018</xref>; <xref ref-type="bibr" rid="B43">Perkins et al., 2021</xref>; <xref ref-type="bibr" rid="B54">Sellers, 2017)</xref>. Além disso, as motivações individuais para o uso de cogumelos psicoativos exercem impacto na configuração dessas experiências, moldando não somente os efeitos agudos vivenciados, mas também reverberam a longo prazo na saúde mental dos usuários <xref ref-type="bibr" rid="B29">(Kaertner et al., 2021)</xref>. Completando a tríade indivíduo-contexto-droga <xref ref-type="bibr" rid="B6">(Borkel et al., 2024; Perkins et al., 2021)</xref>, em vez de considerar a psilocibina somente um facilitador do suporte psicológico, <xref ref-type="bibr" rid="B21">Goodwin et al. (2023)</xref> destacam a necessidade de reconhecer o papel central da psilocibina nos desfechos terapêuticos, argumentando que a intervenção farmacológica da substância pode explicar as modificações nos esquemas cognitivos e rupturas emocionais que levam aos resultados terapêuticos.</p>
         <p>Portanto, a compreensão dos efeitos dos cogumelos psicoativos exige a consideração tanto dos aspectos farmacológicos quanto dos fatores contextuais e individuais. Estudos mais abrangentes, com amostras diversificadas e delineamentos apropriados, são necessários para elucidar a relação entre o uso de cogumelos psicoativos com desfechos de interesse clínico. Investigações longitudinais com usuários de cogumelos permitirão conhecer melhor como este comportamento pode impactar a saúde mental e identificar os fatores associados a menos sintomas psiquiátricos nesta população.</p>
         <p>Os resultados aqui discutidos apresentam limitações que devem ser ponderadas na generalização e interpretação destes achados. O recrutamento realizado por meio de plataformas de mídias sociais resultou em uma amostra autosselecionada, inviabilizando inferências epidemiológicas a partir dos resultados aqui descritos. Além disso, a coleta de dados mediante autorrelato (questionários) pode estar sujeita a vieses de seleção, memória e subjetividade, fatores que podem comprometer a precisão dos dados (<xref ref-type="bibr" rid="B30">Kohlsdorf &amp; Costa, 2009</xref>; <xref ref-type="bibr" rid="B51">Salvador et al., 2020)</xref>. A mensuração dos níveis de depressão, ansiedade e estresse pode estar imprecisa devido ao autorrelato, considerando especialmente a ampla acessibilidade da Internet, tornando os questionários suscetíveis a respostas não sérias, minando potencialmente a validade dos dados coletados por esse meio <xref ref-type="bibr" rid="B22">(Gosling et al., 2004)</xref>.</p>
      </sec>
      <sec sec-type="conclusions">
         <title>Conclusão</title>
         <bold> </bold>
         <p>Este estudo apresentou uma descrição do perfil sociodemográfico, padrões de uso de substâncias psicoativas e saúde mental de usuários de cogumelos psicoativos no Brasil, um grupo pouco investigado. Considerando o crescente interesse científico sobre os potenciais efeitos terapêuticos dos psicodélicos e da ampla presença de cogumelos psicoativos no contexto brasileiro, os resultados contribuem para melhor compreensão desta população. Embora o método do estudo não permita estabelecer relações causais, nossos achados dialogam com pesquisas internacionais que apontam para possíveis impactos positivos do uso de psicodélicos na saúde mental e pode fundamentar estudos futuros que busquem aprofundar essa temática empregando delineamentos longitudinais que possibilitem conhecer de maneira mais precisa os impactos do uso naturalístico de cogumelos sobre a saúde dos usuários.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="B1">
            <mixed-citation>Amorim, E. G. M., &amp; Santos, D. A. R. (2022). O aumento do consumo de álcool e outras drogas durante a pandemia da covid-19 e seus principais impactos na saúde mental de jovens e adultos. <italic>Moitará - Revista do Serviço Social da UNIGRANRIO</italic>, 1(7), 101-114. Recuperado de <ext-link ext-link-type="uri"
                         xlink:href="https://publicacoes.unigranrio.edu.br/mrss/article/view/7348">https://publicacoes.unigranrio.edu.br/mrss/article/view/7348</ext-link>  
            </mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Amorim</surname>
                     <given-names>E. G. M.</given-names>
                  </name>
                  <name>
                     <surname>Santos</surname>
                     <given-names>D. A. R.</given-names>
                  </name>
               </person-group>
               <year>2022</year>
               <article-title>O aumento do consumo de álcool e outras drogas durante a pandemia da covid-19 e seus principais impactos na saúde mental de jovens e adultos</article-title>
               <source>Moitará - Revista do Serviço Social da UNIGRANRIO</source>
               <volume>1</volume>
               <issue>7</issue>
               <fpage>101</fpage>
               <lpage>114</lpage>
               <ext-link ext-link-type="uri"
                         xlink:href="https://publicacoes.unigranrio.edu.br/mrss/article/view/7348">https://publicacoes.unigranrio.edu.br/mrss/article/view/7348</ext-link>
            </element-citation>
         </ref>
         <ref id="B2">
            <mixed-citation>Bastos, F. I. P. M., Vasconcellos, M. T. L., Boni, R. B., Reis, N. B., &amp; Coutinho, C. F. S. (2017). III Levantamento Nacional sobre o uso de drogas pela população brasileira. ICICT/FRIOCRUZ. <ext-link ext-link-type="uri" xlink:href="https://www.arca.fiocruz.br/handle/icict/34614">https://www.arca.fiocruz.br/handle/icict/34614</ext-link> 
            </mixed-citation>
            <element-citation publication-type="report">
               <person-group person-group-type="author">
                  <name>
                     <surname>Bastos</surname>
                     <given-names>F. I. P. M.</given-names>
                  </name>
                  <name>
                     <surname>Vasconcellos</surname>
                     <given-names>M. T. L.</given-names>
                  </name>
                  <name>
                     <surname>Boni</surname>
                     <given-names>R. B.</given-names>
                  </name>
                  <name>
                     <surname>Reis</surname>
                     <given-names>N. B.</given-names>
                  </name>
                  <name>
                     <surname>Coutinho</surname>
                     <given-names>C. F. S.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <source>III Levantamento Nacional sobre o uso de drogas pela população brasileira.</source>
               <publisher-name>ICICT/FRIOCRUZ</publisher-name>
               <ext-link ext-link-type="uri" xlink:href="https://www.arca.fiocruz.br/handle/icict/34614">https://www.arca.fiocruz.br/handle/icict/34614</ext-link>
            </element-citation>
         </ref>
         <ref id="B3">
            <mixed-citation>Bienemann, B., Ruschel, N. S., Campos, M. L., Negreiros, M. A., &amp; Mograbi, D. C. (2020). Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. <italic>PloS One</italic>, 15(2), e0229067. https://doi.org/10.1371/journal.pone.0229067</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Bienemann</surname>
                     <given-names>B.</given-names>
                  </name>
                  <name>
                     <surname>Ruschel</surname>
                     <given-names>N. S.</given-names>
                  </name>
                  <name>
                     <surname>Campos</surname>
                     <given-names>M. L.</given-names>
                  </name>
                  <name>
                     <surname>Negreiros</surname>
                     <given-names>M. A.</given-names>
                  </name>
                  <name>
                     <surname>Mograbi</surname>
                     <given-names>D. C.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Self-reported negative outcomes of psilocybin users: A quantitative textual analysis.</article-title>
               <source>PloS One</source>
               <volume>15</volume>
               <issue>2</issue>
               <elocation-id>e0229067</elocation-id>
               <pub-id pub-id-type="doi">https://doi.org/10.1371/journal.pone.0229067</pub-id>
            </element-citation>
         </ref>
         <ref id="B4">
            <mixed-citation>Biernacki, P., &amp; Waldorf, D. (1981). Snowball sampling: Problems and techniques of chain referral sampling. <italic>Sociological Methods &amp; Research</italic>, 10(2), 141-163. https://doi.org/10.1177/004912418101000205</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Biernacki</surname>
                     <given-names>P.</given-names>
                  </name>
                  <name>
                     <surname>Waldorf</surname>
                     <given-names>D.</given-names>
                  </name>
               </person-group>
               <year>1981</year>
               <article-title>Snowball sampling: Problems and techniques of chain referral sampling.</article-title>
               <source>Sociological Methods &amp; Research</source>
               <volume>10</volume>
               <issue>2</issue>
               <fpage>141</fpage>
               <lpage>163</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/004912418101000205</pub-id>
            </element-citation>
         </ref>
         <ref id="B5">
            <mixed-citation>Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., &amp; Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. <italic>JAMA Psychiatry</italic>, 79(10), 953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Bogenschutz</surname>
                     <given-names>M. P.</given-names>
                  </name>
                  <name>
                     <surname>Ross</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Bhatt</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Baron</surname>
                     <given-names>T.</given-names>
                  </name>
                  <name>
                     <surname>Forcehimes</surname>
                     <given-names>A. A.</given-names>
                  </name>
                  <name>
                     <surname>Laska</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Mennenga</surname>
                     <given-names>S. E.</given-names>
                  </name>
                  <name>
                     <surname>O’Donnell</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Owens</surname>
                     <given-names>L. T.</given-names>
                  </name>
                  <name>
                     <surname>Podrebarac</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Rotrosen</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Tonigan</surname>
                     <given-names>J. S.</given-names>
                  </name>
                  <name>
                     <surname>Worth</surname>
                     <given-names>L.</given-names>
                  </name>
               </person-group>
               <year>2022</year>
               <article-title>Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial</article-title>
               <source>JAMA Psychiatry</source>
               <volume>79</volume>
               <issue>10</issue>
               <fpage>953</fpage>
               <lpage>962</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1001/jamapsychiatry.2022.2096</pub-id>
            </element-citation>
         </ref>
         <ref id="B6">
            <mixed-citation>Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A., Santana Del Pino, Á., &amp; Quintana-Hernández, D. J. (2024). Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: A correlational study. <italic>Expert Review of Clinical Pharmacology</italic>, 17(2), 165-176. https://doi.org/10.1080/17512433.2023.2295997</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Borkel</surname>
                     <given-names>L. F.</given-names>
                  </name>
                  <name>
                     <surname>Rojas-Hernández</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Henríquez-Hernández</surname>
                     <given-names>L. A.</given-names>
                  </name>
                  <name>
                     <surname>Santana Del Pino</surname>
                     <given-names>Á.</given-names>
                  </name>
                  <name>
                     <surname>Quintana-Hernández</surname>
                     <given-names>D. J.</given-names>
                  </name>
               </person-group>
               <year>2024</year>
               <article-title>Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: A correlational study.</article-title>
               <source>Expert Review of Clinical Pharmacology</source>
               <volume>17</volume>
               <issue>2</issue>
               <fpage>165</fpage>
               <lpage>176</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1080/17512433.2023.2295997</pub-id>
            </element-citation>
         </ref>
         <ref id="B7">
            <mixed-citation>Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., &amp; Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. <italic>Psychopharmacology</italic>, 235(2), 399-408. https://doi.org/10.1007/s00213-017-4771-x</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
                  <name>
                     <surname>Bolstridge</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Day</surname>
                     <given-names>C. M. J.</given-names>
                  </name>
                  <name>
                     <surname>Rucker</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Watts</surname>
                     <given-names>R.</given-names>
                  </name>
                  <name>
                     <surname>Erritzoe</surname>
                     <given-names>D. E.</given-names>
                  </name>
                  <name>
                     <surname>Kaelen</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Giribaldi</surname>
                     <given-names>B.</given-names>
                  </name>
                  <name>
                     <surname>Bloomfield</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Pilling</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Rickard</surname>
                     <given-names>J. A.</given-names>
                  </name>
                  <name>
                     <surname>Forbes</surname>
                     <given-names>B.</given-names>
                  </name>
                  <name>
                     <surname>Feilding</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Taylor</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Curran</surname>
                     <given-names>H. V.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D. J.</given-names>
                  </name>
               </person-group>
               <year>2018</year>
               <article-title>Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up.</article-title>
               <source>Psychopharmacology</source>
               <volume>235</volume>
               <issue>2</issue>
               <fpage>399</fpage>
               <lpage>408</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1007/s00213-017-4771-x</pub-id>
            </element-citation>
         </ref>
         <ref id="B8">
            <mixed-citation>Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., &amp; Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. <italic>The Lancet Psychiatry</italic>, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
                  <name>
                     <surname>Bolstridge</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Rucker</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Day</surname>
                     <given-names>C. M. J.</given-names>
                  </name>
                  <name>
                     <surname>Erritzoe</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Kaelen</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Bloomfield</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Rickard</surname>
                     <given-names>J. A.</given-names>
                  </name>
                  <name>
                     <surname>Forbes</surname>
                     <given-names>B.</given-names>
                  </name>
                  <name>
                     <surname>Feilding</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Taylor</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Pilling</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Curran</surname>
                     <given-names>V. H.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D. J.</given-names>
                  </name>
               </person-group>
               <year>2016</year>
               <article-title>Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study.</article-title>
               <source>The Lancet Psychiatry</source>
               <volume>3</volume>
               <issue>7</issue>
               <fpage>619</fpage>
               <lpage>627</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1016/S2215-0366(16)30065-7</pub-id>
            </element-citation>
         </ref>
         <ref id="B9">
            <mixed-citation>Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., &amp; Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. <italic>Scientific Reports</italic>, 7(13187). https://doi.org/10.1038/s41598-017-13282-7</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
                  <name>
                     <surname>Roseman</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Bolstridge</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Demetriou</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Pannekoek</surname>
                     <given-names>J. N.</given-names>
                  </name>
                  <name>
                     <surname>Wall</surname>
                     <given-names>M. B.</given-names>
                  </name>
                  <name>
                     <surname>Tanner</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Kaelen</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>McGonigle</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Murphy</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Leech</surname>
                     <given-names>R.</given-names>
                  </name>
                  <name>
                     <surname>Curran</surname>
                     <given-names>H. V.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D. J.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms.</article-title>
               <source>Scientific Reports</source>
               <volume>7</volume>
               <issue>13187</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.1038/s41598-017-13282-7</pub-id>
            </element-citation>
         </ref>
         <ref id="B10">
            <mixed-citation>Daldegan-Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., &amp; Maia, L. O. (2022). Psychosocial and drug use assessment of regular vs. non-regular ayahuasca users in a Brazilian sample: A web-based survey. <italic>Substance Use &amp; Misuse</italic>, 57(7), 1072-1081. https://doi.org/10.1080/10826084.2022.2063896</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Daldegan-Bueno</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Révész</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Morais</surname>
                     <given-names>P. R.</given-names>
                  </name>
                  <name>
                     <surname>Barbosa</surname>
                     <given-names>P. C. R.</given-names>
                  </name>
                  <name>
                     <surname>Maia</surname>
                     <given-names>L. O.</given-names>
                  </name>
               </person-group>
               <year>2022</year>
               <article-title>Psychosocial and drug use assessment of regular vs. non-regular ayahuasca users in a Brazilian sample: A web-based survey.</article-title>
               <source>Substance Use &amp; Misuse</source>
               <volume>57</volume>
               <issue>7</issue>
               <fpage>1072</fpage>
               <lpage>1081</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1080/10826084.2022.2063896</pub-id>
            </element-citation>
         </ref>
         <ref id="B11">
            <mixed-citation>Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., &amp; Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. <italic>JAMA Psychiatry</italic> , 78(5). https://doi.org/10.1001/jamapsychiatry.2020.3285</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Davis</surname>
                     <given-names>A. K.</given-names>
                  </name>
                  <name>
                     <surname>Barrett</surname>
                     <given-names>F. S.</given-names>
                  </name>
                  <name>
                     <surname>May</surname>
                     <given-names>D. G.</given-names>
                  </name>
                  <name>
                     <surname>Cosimano</surname>
                     <given-names>M. P.</given-names>
                  </name>
                  <name>
                     <surname>Sepeda</surname>
                     <given-names>N. D.</given-names>
                  </name>
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
                  <name>
                     <surname>Finan</surname>
                     <given-names>P. H.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
               </person-group>
               <year>2021</year>
               <article-title>Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial.</article-title>
               <source>JAMA Psychiatry</source>
               <volume>78</volume>
               <issue>5</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.1001/jamapsychiatry.2020.3285</pub-id>
            </element-citation>
         </ref>
         <ref id="B12">
            <mixed-citation>Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., &amp; Griffiths, R. R. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. <italic>The American Journal of Drug and Alcohol Abuse</italic>, 45(2), 161-169. https://doi.org/10.1080/00952990.2018.1545024</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Davis</surname>
                     <given-names>A. K.</given-names>
                  </name>
                  <name>
                     <surname>So</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Lancelotta</surname>
                     <given-names>R.</given-names>
                  </name>
                  <name>
                     <surname>Barsuglia</surname>
                     <given-names>J. P.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
               </person-group>
               <year>2019</year>
               <article-title>5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.</article-title>
               <source>The American Journal of Drug and Alcohol Abuse</source>
               <volume>45</volume>
               <issue>2</issue>
               <fpage>161</fpage>
               <lpage>169</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1080/00952990.2018.1545024</pub-id>
            </element-citation>
         </ref>
         <ref id="B13">
            <mixed-citation>Diniz, O. (1999). Usos, bioquímica e atividade biológica do psilocybe SSP [Monografia, Universidade do Estado do Rio de Janeiro - UERJ] .</mixed-citation>
            <element-citation publication-type="thesis">
               <person-group person-group-type="author">
                  <name>
                     <surname>Diniz</surname>
                     <given-names>O.</given-names>
                  </name>
               </person-group>
               <year>1999</year>
               <source>Usos, bioquímica e atividade biológica do psilocybe SSP</source>
            </element-citation>
         </ref>
         <ref id="B14">
            <mixed-citation>Doblin, R. (2015). From the desk of Rick Doblin, Ph.D. - Summer 2015. Multidisciplinary Association for Psychedelic Studies (MAPS). <ext-link ext-link-type="uri"
                         xlink:href="https://maps.org/news/bulletin/articles/5833-bulletin-summer-2015/5872-from-the-desk-of-rick-doblin-summer-2015">https://maps.org/news/bulletin/articles/5833-bulletin-summer-2015/5872-from-the-desk-of-rick-doblin-summer-2015</ext-link>   
            </mixed-citation>
            <element-citation publication-type="webpage">
               <person-group person-group-type="author">
                  <name>
                     <surname>Doblin</surname>
                     <given-names>R.</given-names>
                  </name>
               </person-group>
               <year>2015</year>
               <source>From the desk of Rick Doblin, Ph.D. - Summer 2015. Multidisciplinary Association for Psychedelic Studies (MAPS).</source>
               <ext-link ext-link-type="uri"
                         xlink:href="https://maps.org/news/bulletin/articles/5833-bulletin-summer-2015/5872-from-the-desk-of-rick-doblin-summer-2015">https://maps.org/news/bulletin/articles/5833-bulletin-summer-2015/5872-from-the-desk-of-rick-doblin-summer-2015</ext-link>
            </element-citation>
         </ref>
         <ref id="B15">
            <mixed-citation>Edmundo, P. (2020). Usos terapêuticos da psilocibina. In F. Beserra &amp; S. Rodrigues, Psicodélicos no Brasil: Ciência e Saúde (p. 49-68). Editora CRV.</mixed-citation>
            <element-citation publication-type="book">
               <person-group person-group-type="author">
                  <name>
                     <surname>Edmundo</surname>
                     <given-names>P.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <chapter-title>Usos terapêuticos da psilocibina.</chapter-title>
               <person-group person-group-type="author">F. BeserraS. Rodrigues</person-group>
               <source>Psicodélicos no Brasil: Ciência e Saúde</source>
               <fpage>49</fpage>
               <lpage>68</lpage>
               <publisher-name>Editora CRV</publisher-name>
            </element-citation>
         </ref>
         <ref id="B16">
            <mixed-citation>Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., &amp; Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. <italic>Acta Psychiatrica Scandinavica</italic>, 138(5), 368-378. https://doi.org/10.1111/acps.12904</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Erritzoe</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Roseman</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Nour</surname>
                     <given-names>M. M.</given-names>
                  </name>
                  <name>
                     <surname>MacLean</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Kaelen</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D. J.</given-names>
                  </name>
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
               </person-group>
               <year>2018</year>
               <article-title>Effects of psilocybin therapy on personality structure.</article-title>
               <source>Acta Psychiatrica Scandinavica</source>
               <volume>138</volume>
               <issue>5</issue>
               <fpage>368</fpage>
               <lpage>378</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1111/acps.12904</pub-id>
            </element-citation>
         </ref>
         <ref id="B17">
            <mixed-citation>Escobar, J. A. C., &amp; Roazzi, A. (2010). Substâncias psicodélicas e psilocibina. Núcleo de Estudos Interdisciplinares sobre Psicoativos-NEIP. Disponivel em: <ext-link ext-link-type="uri"
                         xlink:href="https://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf">https://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf</ext-link> 
            </mixed-citation>
            <element-citation publication-type="webpage">
               <person-group person-group-type="author">
                  <name>
                     <surname>Escobar</surname>
                     <given-names>J. A. C.</given-names>
                  </name>
                  <name>
                     <surname>Roazzi</surname>
                     <given-names>A.</given-names>
                  </name>
               </person-group>
               <year>2010</year>
               <source>Substâncias psicodélicas e psilocibina. Núcleo de Estudos Interdisciplinares sobre Psicoativos-NEIP.</source>
               <ext-link ext-link-type="uri"
                         xlink:href="https://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf">https://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf</ext-link>
            </element-citation>
         </ref>
         <ref id="B18">
            <mixed-citation>Fanhofmann, M. (2019). Ayahuasca e psilocibina - Ensaios sobre ciência, legislação, sociedade, espiritualidade e terapias psicodélicas (2. ed.). Clube dos Autores.</mixed-citation>
            <element-citation publication-type="book">
               <person-group person-group-type="author">
                  <name>
                     <surname>Fanhofmann</surname>
                     <given-names>M.</given-names>
                  </name>
               </person-group>
               <year>2019</year>
               <source>Ayahuasca e psilocibina - Ensaios sobre ciência, legislação, sociedade, espiritualidade e terapias psicodélicas</source>
               <edition>2. ed</edition>
               <publisher-name>Clube dos Autores</publisher-name>
            </element-citation>
         </ref>
         <ref id="B19">
            <mixed-citation>Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., &amp; Johnson, M. W. (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. <italic>Frontiers in Psychiatry</italic>, 10(955). https://doi.org/10.3389/fpsyt.2019.00955</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Garcia-Romeu</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Davis</surname>
                     <given-names>A. K.</given-names>
                  </name>
                  <name>
                     <surname>Erowid</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Erowid</surname>
                     <given-names>F.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey.</article-title>
               <source>Frontiers in Psychiatry</source>
               <volume>10</volume>
               <issue>955</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.3389/fpsyt.2019.00955</pub-id>
            </element-citation>
         </ref>
         <ref id="B20">
            <mixed-citation>Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., &amp; Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. <italic>Journal of Psychopharmacology (Oxford, England)</italic>  , 33(9), 1088-1101. https://doi.org/10.1177/0269881119845793</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Garcia-Romeu</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Davis</surname>
                     <given-names>A. K.</given-names>
                  </name>
                  <name>
                     <surname>Erowid</surname>
                     <given-names>F.</given-names>
                  </name>
                  <name>
                     <surname>Erowid</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
               </person-group>
               <year>2019</year>
               <article-title>Cessation and reduction in alcohol consumption and misuse after psychedelic use.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England)</source>
               <volume>33</volume>
               <issue>9</issue>
               <fpage>1088</fpage>
               <lpage>1101</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881119845793</pub-id>
            </element-citation>
         </ref>
         <ref id="B21">
            <mixed-citation>Goodwin, G. M., Malievskaia, E., Fonzo, G. A., &amp; Nemeroff, C. B. (2023). Must psilocybin always “assist psychotherapy”? <italic>American Journal of Psychiatry</italic>, 181(1), 1-82.  https://doi.org/10.1176/appi.ajp.20221043</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Goodwin</surname>
                     <given-names>G. M.</given-names>
                  </name>
                  <name>
                     <surname>Malievskaia</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Fonzo</surname>
                     <given-names>G. A.</given-names>
                  </name>
                  <name>
                     <surname>Nemeroff</surname>
                     <given-names>C. B.</given-names>
                  </name>
               </person-group>
               <year>2023</year>
               <article-title>Must psilocybin always “assist psychotherapy”? </article-title>
               <source>American Journal of Psychiatry</source>
               <volume>181</volume>
               <issue>1</issue>
               <fpage>1</fpage>
               <lpage>82</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1176/appi.ajp.20221043</pub-id>
            </element-citation>
         </ref>
         <ref id="B22">
            <mixed-citation>Gosling, S. D., Vazire, S., Srivastava, S., &amp; John, O. P. (2004). Should we trust web-based studies? A comparative analysis of six preconceptions about internet questionnaires. <italic>American Psychologist</italic>, 59(2), 93-104. https://doi.org/10.1037/0003-066X.59.2.93</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gosling</surname>
                     <given-names>S. D.</given-names>
                  </name>
                  <name>
                     <surname>Vazire</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Srivastava</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>John</surname>
                     <given-names>O. P.</given-names>
                  </name>
               </person-group>
               <year>2004</year>
               <article-title>Should we trust web-based studies? A comparative analysis of six preconceptions about internet questionnaires.</article-title>
               <source>American Psychologist</source>
               <volume>59</volume>
               <issue>2</issue>
               <fpage>93</fpage>
               <lpage>104</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1037/0003-066X.59.2.93</pub-id>
            </element-citation>
         </ref>
         <ref id="B23">
            <mixed-citation>Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., &amp; Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
                  <name>
                     <surname>Carducci</surname>
                     <given-names>M. A.</given-names>
                  </name>
                  <name>
                     <surname>Umbricht</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Richards</surname>
                     <given-names>W. A.</given-names>
                  </name>
                  <name>
                     <surname>Richards</surname>
                     <given-names>B. D.</given-names>
                  </name>
                  <name>
                     <surname>Cosimano</surname>
                     <given-names>M. P.</given-names>
                  </name>
                  <name>
                     <surname>Klinedinst</surname>
                     <given-names>M. A.</given-names>
                  </name>
               </person-group>
               <year>2016</year>
               <article-title>Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>30</volume>
               <issue>12</issue>
               <fpage>1181</fpage>
               <lpage>1197</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881116675513</pub-id>
            </element-citation>
         </ref>
         <ref id="B24">
            <mixed-citation>Griffiths, R. R., Richards, W. A., McCann, U., &amp; Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. <italic>Psychopharmacology</italic> , 187(3), 268-283. https://doi.org/10.1007/s00213-006-0457-5</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
                  <name>
                     <surname>Richards</surname>
                     <given-names>W. A.</given-names>
                  </name>
                  <name>
                     <surname>McCann</surname>
                     <given-names>U.</given-names>
                  </name>
                  <name>
                     <surname>Jesse</surname>
                     <given-names>R.</given-names>
                  </name>
               </person-group>
               <year>2006</year>
               <article-title>Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.</article-title>
               <source>Psychopharmacology</source>
               <volume>187</volume>
               <issue>3</issue>
               <fpage>268</fpage>
               <lpage>283</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1007/s00213-006-0457-5</pub-id>
            </element-citation>
         </ref>
         <ref id="B25">
            <mixed-citation>Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., &amp; Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. <italic>Archives of General Psychiatry</italic>, 68(1), 71-78. https://doi.org/10.1001/archgenpsychiatry.2010.116</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Grob</surname>
                     <given-names>C. S.</given-names>
                  </name>
                  <name>
                     <surname>Danforth</surname>
                     <given-names>A. L.</given-names>
                  </name>
                  <name>
                     <surname>Chopra</surname>
                     <given-names>G. S.</given-names>
                  </name>
                  <name>
                     <surname>Hagerty</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>McKay</surname>
                     <given-names>C. R.</given-names>
                  </name>
                  <name>
                     <surname>Halberstadt</surname>
                     <given-names>A. L.</given-names>
                  </name>
                  <name>
                     <surname>Greer</surname>
                     <given-names>G. R.</given-names>
                  </name>
               </person-group>
               <year>2011</year>
               <article-title>Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.</article-title>
               <source>Archives of General Psychiatry</source>
               <volume>68</volume>
               <issue>1</issue>
               <fpage>71</fpage>
               <lpage>78</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1001/archgenpsychiatry.2010.116</pub-id>
            </element-citation>
         </ref>
         <ref id="B26">
            <mixed-citation>Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., &amp; Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 28(11), 983-992. https://doi.org/10.1177/0269881114548296</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
                  <name>
                     <surname>Garcia-Romeu</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Cosimano</surname>
                     <given-names>M. P.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
               </person-group>
               <year>2014</year>
               <article-title>Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>28</volume>
               <issue>11</issue>
               <fpage>983</fpage>
               <lpage>992</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881114548296</pub-id>
            </element-citation>
         </ref>
         <ref id="B27">
            <mixed-citation>Johnson, M. W., Garcia-Romeu, A., &amp; Griffiths, R. R. (2017a). Long-term follow-up of psilocybin-facilitated smoking cessation. <italic>The American Journal of Drug and Alcohol Abuse</italic> , 43(1), 55-60. https://doi.org/10.3109/00952990.2016.1170135</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
                  <name>
                     <surname>Garcia-Romeu</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Long-term follow-up of psilocybin-facilitated smoking cessation.</article-title>
               <source>The American Journal of Drug and Alcohol Abuse</source>
               <volume>43</volume>
               <issue>1</issue>
               <fpage>55</fpage>
               <lpage>60</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.3109/00952990.2016.1170135</pub-id>
            </element-citation>
         </ref>
         <ref id="B28">
            <mixed-citation>Johnson, M. W., Garcia-Romeu, A., Johnson, P. S., &amp; Griffiths, R. R. (2017b). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 31(7), 841-850. https://doi.org/10.1177/0269881116684335</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Johnson</surname>
                     <given-names>M. W.</given-names>
                  </name>
                  <name>
                     <surname>Garcia-Romeu</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Johnson</surname>
                     <given-names>P. S.</given-names>
                  </name>
                  <name>
                     <surname>Griffiths</surname>
                     <given-names>R. R.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>31</volume>
               <issue>7</issue>
               <fpage>841</fpage>
               <lpage>850</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881116684335</pub-id>
            </element-citation>
         </ref>
         <ref id="B29">
            <mixed-citation>Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., &amp; Carhart-Harris, R. L. (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. <italic>Scientific Reports</italic> , 11(1941). https://doi.org/10.1038/s41598-021-81446-7</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kaertner</surname>
                     <given-names>L. S.</given-names>
                  </name>
                  <name>
                     <surname>Steinborn</surname>
                     <given-names>M. B.</given-names>
                  </name>
                  <name>
                     <surname>Kettner</surname>
                     <given-names>H.</given-names>
                  </name>
                  <name>
                     <surname>Spriggs</surname>
                     <given-names>M. J.</given-names>
                  </name>
                  <name>
                     <surname>Roseman</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Buchborn</surname>
                     <given-names>T.</given-names>
                  </name>
                  <name>
                     <surname>Balaet</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Timmermann</surname>
                     <given-names>C.</given-names>
                  </name>
                  <name>
                     <surname>Erritzoe</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
               </person-group>
               <year>2021</year>
               <article-title>Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing</article-title>
               <source>Scientific Reports</source>
               <volume>11</volume>
               <issue>1941</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.1038/s41598-021-81446-7</pub-id>
            </element-citation>
         </ref>
         <ref id="B30">
            <mixed-citation>Kohlsdorf, M., &amp; Costa, Á. L., Jr.  (2009). O autorrelato na pesquisa em psicologia da saúde: Desafios metodológicos. <italic>Psicol. Argum</italic>., 27(57), 131-139. <ext-link ext-link-type="uri" xlink:href="http://repositorio.unb.br/handle/10482/6028">http://repositorio.unb.br/handle/10482/6028</ext-link> 
            </mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kohlsdorf</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Costa</surname>
                     <given-names>Á. L.</given-names>
                     <suffix>Jr.</suffix>
                  </name>
               </person-group>
               <year>2009</year>
               <article-title>O autorrelato na pesquisa em psicologia da saúde: Desafios metodológicos.</article-title>
               <source>Psicol. Argum</source>
               <volume>27</volume>
               <issue>57</issue>
               <fpage>131</fpage>
               <lpage>139</lpage>
               <ext-link ext-link-type="uri" xlink:href="http://repositorio.unb.br/handle/10482/6028">http://repositorio.unb.br/handle/10482/6028</ext-link>
            </element-citation>
         </ref>
         <ref id="B31">
            <mixed-citation>Krebs, T. S., &amp; Johansen, P. (2013). Over 30 million psychedelic users in the United States. <italic>F1000Research</italic>, 2(98). https://doi.org/10.12688/f1000research.2-98.v1</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Krebs</surname>
                     <given-names>T. S.</given-names>
                  </name>
                  <name>
                     <surname>Johansen</surname>
                     <given-names>P.</given-names>
                  </name>
               </person-group>
               <year>2013</year>
               <article-title>Over 30 million psychedelic users in the United States.</article-title>
               <source>F1000Research</source>
               <volume>2</volume>
               <issue>98</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.12688/f1000research.2-98.v1</pub-id>
            </element-citation>
         </ref>
         <ref id="B32">
            <mixed-citation>Lipp, M. E. N., &amp; Lipp, L. M. N. (2020). Stress e transtornos mentais durante a pandemia da COVID-19 no Brasil. <italic>Boletim - Academia Paulista de Psicologia</italic>, 40(99), 180-191. <ext-link ext-link-type="uri"
                         xlink:href="http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&amp;pid=S1415-711X2020000200003&amp;lng=pt&amp;tlng=pt">http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&amp;pid=S1415-711X2020000200003&amp;lng=pt&amp;tlng=pt</ext-link>.  </mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lipp</surname>
                     <given-names>M. E. N.</given-names>
                  </name>
                  <name>
                     <surname>Lipp</surname>
                     <given-names>L. M. N.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Stress e transtornos mentais durante a pandemia da COVID-19 no Brasil.</article-title>
               <source>Boletim - Academia Paulista de Psicologia</source>
               <volume>40</volume>
               <issue>99</issue>
               <fpage>180</fpage>
               <lpage>191</lpage>
               <ext-link ext-link-type="uri"
                         xlink:href="http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&amp;pid=S1415-711X2020000200003&amp;lng=pt&amp;tlng=pt">http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&amp;pid=S1415-711X2020000200003&amp;lng=pt&amp;tlng=pt</ext-link>
            </element-citation>
         </ref>
         <ref id="B33">
            <mixed-citation>Lipp, M. E. N., &amp; Lipp, L. M. N. (2022). O impacto da pandemia da covid-19 no nível de stress, saúde mental e valores do ser humano. <italic>Boletim - Academia Paulista de Psicologia</italic> , 42(103), 124-132. https://doi.org/10.5935/2176-3038.20220013</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lipp</surname>
                     <given-names>M. E. N.</given-names>
                  </name>
                  <name>
                     <surname>Lipp</surname>
                     <given-names>L. M. N.</given-names>
                  </name>
               </person-group>
               <year>(2022</year>
               <article-title>O impacto da pandemia da covid-19 no nível de stress, saúde mental e valores do ser humano.</article-title>
               <source>Boletim - Academia Paulista de Psicologia</source>
               <volume>42</volume>
               <issue>103</issue>
               <fpage>124</fpage>
               <lpage>132</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.5935/2176-3038.20220013</pub-id>
            </element-citation>
         </ref>
         <ref id="B34">
            <mixed-citation>Lipp, M. E. N., Sagradim, D. E. V., Saar, M., Araújo, S. R., &amp; Lipp, L. M. N. (2023). Stress no Brasil 2022: A herança da pandemia da coivd-19. <italic>Boletim - Academia Paulista de Psicologia</italic> , 43(104), 26-37. https://doi.org/10.5935/2176-3038.20230004</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lipp</surname>
                     <given-names>M. E. N.</given-names>
                  </name>
                  <name>
                     <surname>Sagradim</surname>
                     <given-names>D. E. V.</given-names>
                  </name>
                  <name>
                     <surname>Saar</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Araújo</surname>
                     <given-names>S. R.</given-names>
                  </name>
                  <name>
                     <surname>Lipp</surname>
                     <given-names>L. M. N.</given-names>
                  </name>
               </person-group>
               <year>2023</year>
               <article-title>Stress no Brasil 2022: A herança da pandemia da coivd-19.</article-title>
               <source>Boletim - Academia Paulista de Psicologia</source>
               <volume>43</volume>
               <issue>104</issue>
               <fpage>26</fpage>
               <lpage>37</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.5935/2176-3038.20230004</pub-id>
            </element-citation>
         </ref>
         <ref id="B35">
            <mixed-citation>Lovibond, S. H., &amp; Lovibond, P. F. (2004). Manual for the Depression Anxiety Stress Scales (4o ed). Psychology Foundation.</mixed-citation>
            <element-citation publication-type="book">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lovibond</surname>
                     <given-names>S. H.</given-names>
                  </name>
                  <name>
                     <surname>Lovibond</surname>
                     <given-names>P. F.</given-names>
                  </name>
               </person-group>
               <year>2004</year>
               <source>Manual for the Depression Anxiety Stress Scales</source>
               <edition>4o ed</edition>
               <publisher-name>Psychology Foundation</publisher-name>
            </element-citation>
         </ref>
         <ref id="B36">
            <mixed-citation>Ministério da Saúde. (1998). Portaria no 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial. Diário Oficial da União. <ext-link ext-link-type="uri"
                         xlink:href="https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html">https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html</ext-link>  
            </mixed-citation>
            <element-citation publication-type="legal-doc">
               <person-group person-group-type="author">
                  <collab>Ministério da Saúde</collab>
               </person-group>
               <year>1998</year>
               <source>Portaria no 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial.</source>
               <publisher-name>Diário Oficial da União.</publisher-name>
               <ext-link ext-link-type="uri"
                         xlink:href="https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html">https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html</ext-link>
            </element-citation>
         </ref>
         <ref id="B37">
            <mixed-citation>Morais, P. R., Areco, N. K. C., Fidalgo, T. M., &amp; Silveira, D. X. (2022). Mental health and quality of life in a population of recreative cannabis users in Brazil. <italic>Journal of Psychiatric Research</italic>, 146, 11-20. https://doi.org/10.1016/j.jpsychires.2021.12.010</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Morais</surname>
                     <given-names>P. R.</given-names>
                  </name>
                  <name>
                     <surname>Areco</surname>
                     <given-names>N. K. C.</given-names>
                  </name>
                  <name>
                     <surname>Fidalgo</surname>
                     <given-names>T. M.</given-names>
                  </name>
                  <name>
                     <surname>Silveira</surname>
                     <given-names>D. X.</given-names>
                  </name>
               </person-group>
               <year>2022</year>
               <article-title>Mental health and quality of life in a population of recreative cannabis users in Brazil.</article-title>
               <source>Journal of Psychiatric Research</source>
               <volume>146</volume>
               <fpage>11</fpage>
               <lpage>20</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1016/j.jpsychires.2021.12.010</pub-id>
            </element-citation>
         </ref>
         <ref id="B38">
            <mixed-citation>Nichols, D. E. (2014). The Heffter Research Institute: Past and hopeful future. <italic>Journal of Psychoactive Drugs</italic>, 46(1), 20-26. https://doi.org/10.1080/02791072.2014.873688</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Nichols</surname>
                     <given-names>D. E.</given-names>
                  </name>
               </person-group>
               <year>2014</year>
               <article-title>The Heffter Research Institute: Past and hopeful future.</article-title>
               <source>Journal of Psychoactive Drugs</source>
               <volume>46</volume>
               <issue>1</issue>
               <fpage>20</fpage>
               <lpage>26</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1080/02791072.2014.873688</pub-id>
            </element-citation>
         </ref>
         <ref id="B39">
            <mixed-citation>Nichols, D. E. (2016). Psychedelics. <italic>Pharmacological Reviews</italic>, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Nichols</surname>
                     <given-names>D. E.</given-names>
                  </name>
               </person-group>
               <year>2016</year>
               <article-title>Psychedelics</article-title>
               <source>Pharmacological Reviews</source>
               <volume>68</volume>
               <issue>2</issue>
               <fpage>264</fpage>
               <lpage>355</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1124/pr.115.011478</pub-id>
            </element-citation>
         </ref>
         <ref id="B40">
            <mixed-citation>Orsolini, L., Papanti, G. D., Francesconi, G., &amp; Schifano, F. (2015). Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. <italic>Cyberpsychology, Behavior and Social Networking</italic>, 18(5), 296-300. https://doi.org/10.1089/cyber.2014.0486</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Orsolini</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Papanti</surname>
                     <given-names>G. D.</given-names>
                  </name>
                  <name>
                     <surname>Francesconi</surname>
                     <given-names>G.</given-names>
                  </name>
                  <name>
                     <surname>Schifano</surname>
                     <given-names>F.</given-names>
                  </name>
               </person-group>
               <year>2015</year>
               <article-title>Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts.</article-title>
               <source>Cyberpsychology, Behavior and Social Networking</source>
               <volume>18</volume>
               <issue>5</issue>
               <fpage>296</fpage>
               <lpage>300</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1089/cyber.2014.0486</pub-id>
            </element-citation>
         </ref>
         <ref id="B41">
            <mixed-citation>Orsolini, L., John-Smith, P., St., McQueen, D., Papanti, D., Corkery, J., &amp; Schifano, F.   (2017). Evolutionary considerations on the emerging subculture of the e-psychonauts and the novel psychoactive substances: A comeback to the shamanism? <italic>Current Neuropharmacology</italic>, 15(5), 731-737. https://doi.org/10.2174/1570159X15666161111114838</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Orsolini</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>John-Smith</surname>
                     <given-names>P.</given-names>
                  </name>
                  <name>
                     <surname>St.</surname>
                     <given-names>McQueen</given-names>
                  </name>
                  <name>
                     <surname>D.</surname>
                     <given-names>Papanti</given-names>
                  </name>
                  <name>
                     <surname>D.</surname>
                     <given-names>Corkery</given-names>
                  </name>
                  <name>
                     <surname>J.</surname>
                     <given-names>Schifano</given-names>
                  </name>
                  <name>
                     <surname>F.</surname>
                     <given-names/>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Evolutionary considerations on the emerging subculture of the e-psychonauts and the novel psychoactive substances: A comeback to the shamanism?</article-title>
               <source>Current Neuropharmacology</source>
               <volume>15</volume>
               <issue>5</issue>
               <fpage>731</fpage>
               <lpage>737</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.2174/1570159X15666161111114838</pub-id>
            </element-citation>
         </ref>
         <ref id="B42">
            <mixed-citation>Passie, T., Seifert, J., Schneider, U., &amp; Emrich, H. M. (2002). The pharmacology of psilocybin. <italic>Addiction Biology</italic>, 7(4), 357-364. https://doi.org/10.1080/1355621021000005937</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Passie</surname>
                     <given-names>T.</given-names>
                  </name>
                  <name>
                     <surname>Seifert</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Schneider</surname>
                     <given-names>U.</given-names>
                  </name>
                  <name>
                     <surname>Emrich</surname>
                     <given-names>H. M.</given-names>
                  </name>
               </person-group>
               <year>2002</year>
               <article-title>The pharmacology of psilocybin.</article-title>
               <source>Addiction Biology</source>
               <volume>7</volume>
               <issue>4</issue>
               <fpage>357</fpage>
               <lpage>364</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1080/1355621021000005937</pub-id>
            </element-citation>
         </ref>
         <ref id="B43">
            <mixed-citation>Perkins, D., Schubert, V., Simonová, H., Tófoli, L. F., Bouso, J. C., Horák, M., Galvão-Coelho, N. L., &amp; Sarris, J. (2021). Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: Results of a large international survey. <italic>Frontiers in Pharmacology</italic>, 12(623979). https://doi.org/10.3389/fphar.2021.623979</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Perkins</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Schubert</surname>
                     <given-names>V.</given-names>
                  </name>
                  <name>
                     <surname>Simonová</surname>
                     <given-names>H.</given-names>
                  </name>
                  <name>
                     <surname>Tófoli</surname>
                     <given-names>L. F.</given-names>
                  </name>
                  <name>
                     <surname>Bouso</surname>
                     <given-names>J. C.</given-names>
                  </name>
                  <name>
                     <surname>Horák</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Galvão-Coelho</surname>
                     <given-names>N. L.</given-names>
                  </name>
                  <name>
                     <surname>Sarris</surname>
                     <given-names>J.</given-names>
                  </name>
               </person-group>
               <year>2021</year>
               <article-title>Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: Results of a large international survey. </article-title>
               <source>Frontiers in Pharmacology</source>
               <volume>12</volume>
               <issue>623979</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.3389/fphar.2021.623979</pub-id>
            </element-citation>
         </ref>
         <ref id="B44">
            <mixed-citation>Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. <italic>Journal of Humanistic Psychology</italic>, 57(5), 450-487. https://doi.org/10.1177/0022167817711304</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Phelps</surname>
                     <given-names>J.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Developing guidelines and competencies for the training of psychedelic therapists.</article-title>
               <source>Journal of Humanistic Psychology</source>
               <volume>57</volume>
               <issue>5</issue>
               <fpage>450</fpage>
               <lpage>487</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0022167817711304</pub-id>
            </element-citation>
         </ref>
         <ref id="B45">
            <mixed-citation>Ramos, F. P., Reis, L. B., Iglesias, A., Andrade, A. L. D., Gandra, C. T., &amp; Costa, E. F. (2024). Consumo de drogas como estratégia de regulação emocional durante pandemia de COVID-19. <italic>Revista Psicologia em Pesquisa</italic>, 18(3). https://doi.org/10.34019/1982-1247.2024.v18.36131</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ramos</surname>
                     <given-names>F. P.</given-names>
                  </name>
                  <name>
                     <surname>Reis</surname>
                     <given-names>L. B.</given-names>
                  </name>
                  <name>
                     <surname>Iglesias</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Andrade</surname>
                     <given-names>A. L. D.</given-names>
                  </name>
                  <name>
                     <surname>Gandra</surname>
                     <given-names>C. T.</given-names>
                  </name>
                  <name>
                     <surname>Costa</surname>
                     <given-names>E. F.</given-names>
                  </name>
               </person-group>
               <year>2024</year>
               <article-title>Consumo de drogas como estratégia de regulação emocional durante pandemia de COVID-19.</article-title>
               <source>Revista Psicologia em Pesquisa</source>
               <volume>18</volume>
               <issue>3</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.34019/1982-1247.2024.v18.36131</pub-id>
            </element-citation>
         </ref>
         <ref id="B46">
            <mixed-citation>Roberts, C. A., Osborne-Miller, I., Cole, J., Gage, S. H., &amp; Christiansen, P. (2020). Perceived harm, motivations for use and subjective experiences of recreational psychedelic “magic” mushroom use. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 34(9), 999-1007. https://doi.org/10.1177/0269881120936508</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Roberts</surname>
                     <given-names>C. A.</given-names>
                  </name>
                  <name>
                     <surname>Osborne-Miller</surname>
                     <given-names>I.</given-names>
                  </name>
                  <name>
                     <surname>Cole</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Gage</surname>
                     <given-names>S. H.</given-names>
                  </name>
                  <name>
                     <surname>Christiansen</surname>
                     <given-names>P.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Perceived harm, motivations for use and subjective experiences of recreational psychedelic “magic” mushroom use.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>34</volume>
               <issue>9</issue>
               <fpage>999</fpage>
               <lpage>1007</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881120936508</pub-id>
            </element-citation>
         </ref>
         <ref id="B47">
            <mixed-citation>Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., &amp; Walsh, Z. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. <italic>Scientific Reports</italic> , 11(22479). https://doi.org/10.1038/s41598-021-01811-4</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Rootman</surname>
                     <given-names>J. M.</given-names>
                  </name>
                  <name>
                     <surname>Kryskow</surname>
                     <given-names>P.</given-names>
                  </name>
                  <name>
                     <surname>Harvey</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Stamets</surname>
                     <given-names>P.</given-names>
                  </name>
                  <name>
                     <surname>Santos-Brault</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Kuypers</surname>
                     <given-names>K. P. C.</given-names>
                  </name>
                  <name>
                     <surname>Polito</surname>
                     <given-names>V.</given-names>
                  </name>
                  <name>
                     <surname>Bourzat</surname>
                     <given-names>F.</given-names>
                  </name>
                  <name>
                     <surname>Walsh</surname>
                     <given-names>Z.</given-names>
                  </name>
               </person-group>
               <year>2021</year>
               <article-title>Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.</article-title>
               <source>Scientific Reports</source>
               <volume>11</volume>
               <issue>22479</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.1038/s41598-021-01811-4</pub-id>
            </element-citation>
         </ref>
         <ref id="B48">
            <mixed-citation>Roseman, L., Nutt, D. J., &amp; Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. <italic>Frontiers in Pharmacology</italic> , 8(974). https://doi.org/10.3389/fphar.2017.00974</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Roseman</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D. J.</given-names>
                  </name>
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R. L.</given-names>
                  </name>
               </person-group>
               <year>2018</year>
               <article-title>Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. </article-title>
               <source>Frontiers in Pharmacology</source>
               <volume>8</volume>
               <issue>974</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.3389/fphar.2017.00974</pub-id>
            </element-citation>
         </ref>
         <ref id="B49">
            <mixed-citation>Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L., Hui, K., &amp; Hapke, E. (2020). Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 34(6), 612-622. https://doi.org/10.1177/0269881120908004</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Rosenbaum</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Weissman</surname>
                     <given-names>C.</given-names>
                  </name>
                  <name>
                     <surname>Anderson</surname>
                     <given-names>T.</given-names>
                  </name>
                  <name>
                     <surname>Petranker</surname>
                     <given-names>R.</given-names>
                  </name>
                  <name>
                     <surname>Dinh-Williams</surname>
                     <given-names>L.</given-names>
                  </name>
                  <name>
                     <surname>Hui</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Hapke</surname>
                     <given-names>E.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>34</volume>
               <issue>6</issue>
               <fpage>612</fpage>
               <lpage>622</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881120908004</pub-id>
            </element-citation>
         </ref>
         <ref id="B50">
            <mixed-citation>Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., &amp; Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. <italic>Journal of Psychopharmacology (Oxford, England)</italic> , 30(12), 1165-1180. https://doi.org/10.1177/0269881116675512</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ross</surname>
                     <given-names>S.</given-names>
                  </name>
                  <name>
                     <surname>Bossis</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Guss</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Agin-Liebes</surname>
                     <given-names>G.</given-names>
                  </name>
                  <name>
                     <surname>Malone</surname>
                     <given-names>T.</given-names>
                  </name>
                  <name>
                     <surname>Cohen</surname>
                     <given-names>B.</given-names>
                  </name>
                  <name>
                     <surname>Mennenga</surname>
                     <given-names>S. E.</given-names>
                  </name>
                  <name>
                     <surname>Belser</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Kalliontzi</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Babb</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Su</surname>
                     <given-names>Z.</given-names>
                  </name>
                  <name>
                     <surname>Corby</surname>
                     <given-names>P.</given-names>
                  </name>
                  <name>
                     <surname>Schmidt</surname>
                     <given-names>B. L.</given-names>
                  </name>
               </person-group>
               <year>2016</year>
               <article-title>Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial.</article-title>
               <source>Journal of Psychopharmacology (Oxford, England) </source>
               <volume>30</volume>
               <issue>12</issue>
               <fpage>1165</fpage>
               <lpage>1180</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0269881116675512</pub-id>
            </element-citation>
         </ref>
         <ref id="B51">
            <mixed-citation>Salvador, P. T. C. O., Alves, K. Y. A., Rodrigues, C. C. F. M., &amp; Oliveira, L. V. (2020). Estratégias de coleta de dados online nas pesquisas qualitativas da área da saúde: Scoping review. <italic>Revista Gaúcha de Enfermagem</italic>, 41(e20190297). https://doi.org/10.1590/1983-1447.2020.20190297</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Salvador</surname>
                     <given-names>P. T. C. O.</given-names>
                  </name>
                  <name>
                     <surname>Alves</surname>
                     <given-names>K. Y. A.</given-names>
                  </name>
                  <name>
                     <surname>Rodrigues</surname>
                     <given-names>C. C. F. M.</given-names>
                  </name>
                  <name>
                     <surname>Oliveira</surname>
                     <given-names>L. V.</given-names>
                  </name>
               </person-group>
               <year>2020</year>
               <article-title>Estratégias de coleta de dados online nas pesquisas qualitativas da área da saúde: Scoping review.</article-title>
               <source>Revista Gaúcha de Enfermagem</source>
               <volume>41</volume>
               <issue>e20190297</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.1590/1983-1447.2020.20190297</pub-id>
            </element-citation>
         </ref>
         <ref id="B52">
            <mixed-citation>Schenberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A paradigm shift in psychiatric research and development. <italic>Frontiers in Pharmacology</italic> , 9(733). https://doi.org/10.3389/fphar.2018.00733</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Schenberg</surname>
                     <given-names>E. E.</given-names>
                  </name>
               </person-group>
               <year>2018</year>
               <article-title>Psychedelic-Assisted Psychotherapy: A paradigm shift in psychiatric research and development.</article-title>
               <source>Frontiers in Pharmacology</source>
               <volume>9</volume>
               <issue>733</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.3389/fphar.2018.00733</pub-id>
            </element-citation>
         </ref>
         <ref id="B53">
            <mixed-citation>Schultes, R. E. (1969). Hallucinogens of plant origin: Interdisciplinary studies of plants sacred in primitive cultures yield results of academic and practical interest. <italic>Science (New York, N.Y.)</italic>, 163(3864), 245-254. https://doi.org/10.1126/science.163.3864.245</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Schultes</surname>
                     <given-names>R. E.</given-names>
                  </name>
               </person-group>
               <year>1969</year>
               <article-title>Hallucinogens of plant origin: Interdisciplinary studies of plants sacred in primitive cultures yield results of academic and practical interest.</article-title>
               <source>Science (New York, N.Y.)</source>
               <volume>163</volume>
               <issue>3864</issue>
               <fpage>245</fpage>
               <lpage>254</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1126/science.163.3864.245</pub-id>
            </element-citation>
         </ref>
         <ref id="B54">
            <mixed-citation>Sellers, E. M. (2017). Psilocybin: Good trip or bad trip. <italic>Clinical Pharmacology and Therapeutics</italic>, 102(4), 580-584. https://doi.org/10.1002/cpt.697</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Sellers</surname>
                     <given-names>E. M.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Psilocybin: Good trip or bad trip.</article-title>
               <source>Clinical Pharmacology and Therapeutics</source>
               <volume>102</volume>
               <issue>4</issue>
               <fpage>580</fpage>
               <lpage>584</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1002/cpt.697</pub-id>
            </element-citation>
         </ref>
         <ref id="B55">
            <mixed-citation> Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., &amp; Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. <italic>Frontiers in Psychiatry</italic> , 14(1134454). https://doi.org/10.3389/fpsyt.2023.1134454</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Meer</surname>
                     <given-names>P. B.</given-names>
                  </name>
                  <name>
                     <surname>Fuentes</surname>
                     <given-names>J. J.</given-names>
                  </name>
                  <name>
                     <surname>Kaptein</surname>
                     <given-names>A. A.</given-names>
                  </name>
                  <name>
                     <surname>Schoones</surname>
                     <given-names>J. W.</given-names>
                  </name>
                  <name>
                     <surname>Waal</surname>
                     <given-names>M. M.</given-names>
                  </name>
                  <name>
                     <surname>Goudriaan</surname>
                     <given-names>A. E.</given-names>
                  </name>
                  <name>
                     <surname>Kramers</surname>
                     <given-names>K.</given-names>
                  </name>
                  <name>
                     <surname>Schellekens</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Somers</surname>
                     <given-names>M.</given-names>
                  </name>
                  <name>
                     <surname>Bossong</surname>
                     <given-names>M. G.</given-names>
                  </name>
                  <name>
                     <surname>Batalla</surname>
                     <given-names>A.</given-names>
                  </name>
               </person-group>
               <year>2023</year>
               <article-title>Therapeutic effect of psilocybin in addiction: A systematic review.</article-title>
               <source>Frontiers in Psychiatry</source>
               <volume>14</volume>
               <issue>1134454</issue>
               <pub-id pub-id-type="doi">https://doi.org/10.3389/fpsyt.2023.1134454</pub-id>
            </element-citation>
         </ref>
         <ref id="B56">
            <mixed-citation>Vignola, R. C. B. (2013). Escala de depressão, ansiedade e estresse (DASS): Adaptação e validação para o português do Brasil [Dissertação de Mestrado, Universidade Federal de São Paulo]. <ext-link ext-link-type="uri"
                         xlink:href="https://repositorio.unifesp.br/handle/11600/48328">https://repositorio.unifesp.br/handle/11600/48328</ext-link>    
            </mixed-citation>
            <element-citation publication-type="thesis">
               <person-group person-group-type="author">
                  <name>
                     <surname>Vignola</surname>
                     <given-names>R. C. B.</given-names>
                  </name>
               </person-group>
               <year>2013</year>
               <source>Escala de depressão, ansiedade e estresse (DASS): Adaptação e validação para o português do Brasil</source>
               <ext-link ext-link-type="uri"
                         xlink:href="https://repositorio.unifesp.br/handle/11600/48328">https://repositorio.unifesp.br/handle/11600/48328</ext-link>
            </element-citation>
         </ref>
         <ref id="B57">
            <mixed-citation>Vignola, R. C. B., &amp; Tucci, A. M. (2014). Adaptation and validation of the depression, anxiety and stress scale (DASS) to Brazilian Portuguese. <italic>Journal of Affective Disorders</italic>, 155, 104-109. https://doi.org/10.1016/j.jad.2013.10.031</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Vignola</surname>
                     <given-names>R. C. B.</given-names>
                  </name>
                  <name>
                     <surname>Tucci</surname>
                     <given-names>A. M.</given-names>
                  </name>
               </person-group>
               <year>2014</year>
               <article-title>Adaptation and validation of the depression, anxiety and stress scale (DASS) to Brazilian Portuguese. </article-title>
               <source>Journal of Affective Disorders</source>
               <volume>155</volume>
               <fpage>104</fpage>
               <lpage>109</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1016/j.jad.2013.10.031</pub-id>
            </element-citation>
         </ref>
         <ref id="B58">
            <mixed-citation>Watts, R., Day, C., Krzanowski, J., Nutt, D., &amp; Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. <italic>Journal of Humanistic Psychology</italic> , 57(5) 520-564. https://doi.org/10.1177/0022167817709585</mixed-citation>
            <element-citation publication-type="journal">
               <person-group person-group-type="author">
                  <name>
                     <surname>Watts</surname>
                     <given-names>R.</given-names>
                  </name>
                  <name>
                     <surname>Day</surname>
                     <given-names>C.</given-names>
                  </name>
                  <name>
                     <surname>Krzanowski</surname>
                     <given-names>J.</given-names>
                  </name>
                  <name>
                     <surname>Nutt</surname>
                     <given-names>D.</given-names>
                  </name>
                  <name>
                     <surname>Carhart-Harris</surname>
                     <given-names>R.</given-names>
                  </name>
               </person-group>
               <year>2017</year>
               <article-title>Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression.</article-title>
               <source>Journal of Humanistic Psychology</source>
               <volume>57</volume>
               <issue>5</issue>
               <fpage>520</fpage>
               <lpage>564</lpage>
               <pub-id pub-id-type="doi">https://doi.org/10.1177/0022167817709585</pub-id>
            </element-citation>
         </ref>
         <ref id="B59">
            <mixed-citation>Winstock, A. R., Timmerman, C., Davies, E., Maier, L. J., Zhuparris, A., Ferris, J. A., Barratt, M. J., &amp; Kuypers, K. P. C. (2021). GDS 2020 Psychedelics Key Finding Report. Global Drug Survey (GDS).</mixed-citation>
            <element-citation publication-type="book">
               <person-group person-group-type="author">
                  <name>
                     <surname>Winstock</surname>
                     <given-names>A. R.</given-names>
                  </name>
                  <name>
                     <surname>Timmerman</surname>
                     <given-names>C.</given-names>
                  </name>
                  <name>
                     <surname>Davies</surname>
                     <given-names>E.</given-names>
                  </name>
                  <name>
                     <surname>Maier</surname>
                     <given-names>L. J.</given-names>
                  </name>
                  <name>
                     <surname>Zhuparris</surname>
                     <given-names>A.</given-names>
                  </name>
                  <name>
                     <surname>Ferris</surname>
                     <given-names>J. A.</given-names>
                  </name>
                  <name>
                     <surname>Barratt</surname>
                     <given-names>M. J.</given-names>
                  </name>
                  <name>
                     <surname>Kuypers</surname>
                     <given-names>K. P. C.</given-names>
                  </name>
               </person-group>
               <year>2021</year>
               <source>GDS 2020 Psychedelics Key Finding Report.</source>
               <publisher-name>Global Drug Survey (GDS).</publisher-name>
            </element-citation>
         </ref>
      </ref-list>
   </back>
</article>